Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIZE benralizumab influenza vaccine response study
2016-001717-24Phase 3
- Sponsor
- AstraZeneca
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and severe asthma comparing Benralizumab with Placebo (2 arms). Primary endpoint: Post-dose strain-specific hemagglutination-inhibition antibody geometric mean fold rises.
02
Drugs
benralizumab
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on 2016-001717-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001717-24.